Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms.

Blood advances - 14 Jun 2022

Schimmer Roman R, Kovtonyuk Larisa V, Klemm Nancy, Fullin Jonas, Stolz Sebastian M, Mueller Jan, Caiado Francisco, Kurppa Kari J, Ebert Benjamin L, Manz Markus G, Boettcher Steffen

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Share to Neoplasms

Share to Proto-Oncogene Proteins c-bcl-2

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 35026842
DOI: 10.1182/bloodadvances.2021005859
PMCID: PMC9198927

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms.PMID 35026842Read ↗

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype.Semantic proximity Read ↗

TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management.Semantic proximity Read ↗

TP53-altered higher-risk myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a distinct genetic entity with unique unmet needs.Semantic proximity Read ↗

TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches.Semantic proximity Read ↗

Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemiaSemantic proximity Read ↗

What have we learned about TP53-mutated acute myeloid leukemia?Semantic proximity Read ↗

AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy.Semantic proximity Read ↗

Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical DevelopmentsSemantic proximity Read ↗

Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms.Semantic proximity Read ↗

The Prognostic Ability of RAS Pathway-Related Gene Mutations in Patients with Myeloid Neoplasms Treated with Hypomethylating Agents.Semantic proximity Read ↗

Venetoclax and hypomethylating agents in TP53‐mutated acute myeloid leukaemiaSemantic proximity Read ↗

Targeting TP53 Mutations in Myelodysplastic Syndromes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.